1 / 1

Faslodex(Fulvestrant)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

Injection

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

FASLODEX® (fulvestrant) is a prescription medication used to treat hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women. It can be administered as a monotherapy or in combination with targeted therapies such as ribociclib, palbociclib, or abemaciclib. The drug works by inhibiting the estrogen receptor, effectively blocking the growth of estrogen-dependent breast cancer cells. FASLODEX® is administered intramuscularly and has a carefully designed schedule of administration to optimize efficacy and reduce the risk of adverse effects.

This treatment is specifically designed for postmenopausal women who have either not received prior endocrine therapy or whose disease has progressed after initial endocrine treatment. FASLODEX® provides a critical therapeutic option for managing advanced breast cancer by targeting estrogen receptor signaling, a key pathway involved in tumor growth in hormone-sensitive cancers.

Generic name

Faslodex(Fulvestrant)

English name

Fulvestrant

Alternative Names

Faslodex

Drug prices

Indications

FASLODEX is indicated for the treatment of:

Hormone receptor (HR)-positive, HER2-negative advanced breast cancer in postmenopausal women who have not previously been treated with endocrine therapy.

HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.

HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine-based therapy or following disease progression on endocrine therapy.

HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therap

Therapeutic Target

Estrogen receptor (ER)

Active Ingredients

Fulvestrant (250 mg per 5 mL)

Dosage form

Injection

specifications

FASLODEX is supplied as 250 mg per 5 mL in a vial for intramuscular injection.

Description

FASLODEX (fulvestrant) is a selective estrogen receptor antagonist used in the treatment of HR-positive, HER2-negative breast cancer in postmenopausal women. It works by binding to the estrogen receptor and preventing its activation, thus inhibiting the growth of estrogen-dependent breast cancer cells.

Dosage and Administration

Dosage for Adults:

The recommended dose is 500 mg (2 x 5 mL injections of 250 mg/5 mL) administered intramuscularly into the buttocks (gluteal area) on Days 1, 15, 29, and once monthly thereafter.

In patients with moderate hepatic impairment, the recommended dose is reduced to 250 mg (1 x 5 mL injection of 250 mg/5 mL), following the same administration schedule.

Administration:

Administer FASLODEX slowly, over 1-2 minutes per injection, at the dorsogluteal or ventrogluteal site. Exercise caution to avoid the sciatic nerve during injection.

CATEGORY NAVIGATION